Exhibit 1:

Description of Scenarios

Scenarios	Costs	Impact
New Drug treatments	Rituximab to treat Non-Hodgkin lymphomas: $10,000 per patient; Trastuzumab (Herceptin) to treat metastatic breast cancer (30% of all breast cancer): $2,300 per patient; Tamoxifen to treat DCIS or stage 1 breast cancer (70% of all breast cancer): $8,210 per patient; Oxaliplatin to treat stage III and IV colorectal cancer (60% of all colorectal cancer): $11,826 per patient; Leuprolide acetate (Lupron) to treat prostate cancer: $700 per patient; and Temozolomide (Temodar) to treat brain cancer: $27,878; Costs for side effect medication: $10,000 per patient.	Rituximab: relative risk reduction of 33%; Trastuzumab: relative risk reduction of 20%; Tamoxifen: relative risk reduction of 37%; Oxaliplatin: relative risk reduction of 23%; Leuprolide acetate: relative risk reduction of 52%; Temozolomide (Temodar): relative risk reduction of 28%.
Cancer Vaccines	$488.15 per person	Everyone who does not have cancer takes the vaccine which would prevent them from having cancer in the future.
Cure for Cancer	$10,000 per cancer patient	Assume that no one in the entering 65 years old cohort has cancer at the time. Cancer is treated immediately after its incidence and would be cured in the same year.
Early detection (Zero Cost)	No cost	All cancer diagnosed is at the early stage as a result of a better screening test.
Early detection (Moderate Cost)	$100 per person per year for beneficiaries without cancer	All cancer diagnosed is at the early stage as a result of a better screening test.